NAS10026,990+1.35%S&P7,377+0.31%GOLD$4,075−0.94%BTC$75,624−0.16%VIX25.64−9.01%latest tape · as of 02:03 UTC
The Screen · Industrials · Specialty Industrial Machinery
NDSNNordson Corporation
NDSN · a US exchange · USD · Market cap $18.0B · 8,200 employees
Nordson Corporation engineers, manufactures, and markets products and systems to dispense, apply, and control adhesives, coatings, polymers, sealants, biomaterials, medical components, and other fluids.
FAIL · Does not pass the screen
309.86 USD
Price as of 6 Nov 2026Daily close, not a live quote
Screened 2026-11-06 · the tape above runs as of 02:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price309.86 USD at the 6 Nov 2026 close
Our value readFair vs our fair value, as of 6 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.31, read 2026-11-03
Ethical does not pass the values gate
Price309.86 USD
Fair value309.83
Ethical score10.0/100
Value readFairas of 6 Nov 2026
Our investment reviews on this name
2026-10-02Read Accumulation331.32-6.5% to today Markup gives way to Accumulation after a 6% rise in 2 weeks
2026-09-18Read Markup313.94-1.3% to today Accumulation gives way to Markup first Markup read since August
2026-08-16Read Accumulation308.98+0.3% to today ✓Markup gives way to Accumulation after a 9% rise in 6 weeks
2026-07-02Read Markup282.73+9.6% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Nordson Corporation holds its Distribution at $309.86. The statistical read favours the sellers, held for 50 days.
As held on the ledger · 2026-11-06
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 50 days
Price at the screen
$309.86
Valuation
32.66 trailing · 24.85 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.99
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
35.36%
Below 33%
Interest-bearing debt is 35.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
11.18%
Below 49%
Money owed to the company is 11.2% of assets, under the 49% limit.
Pass
Revenue purity
0.11%
Below 5%
Only 0.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Nordson's business is in a permissible area, but its interest-bearing debt is about 35% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when NDSN's ethical verdict changes
Today NDSN does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 6 Nov 2026: moderate competitive moat, 10.30% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. The price runs 0.0% above the base estimate.
Third-party analyst targets. The average target sits +16% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $309.83, with a range of $253.80 to $356.30, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Nordson sits at fair value yet fails ethics
Picture a factory line where every seal, coating and medical component needs precise fluid control. Nordson supplies that equipment across dozens of end markets and grows revenue at 8 percent a year with an 18 percent profit margin and 17 percent ROE. The shares trade right on our fair value estimate, leaving no margin of safety.
We pass for one clear reason. The company fails our ethical screen on its debt ratio, a structural issue that outweighs the moderate moat and steady growth. Analyst targets sit higher, yet price and ethics together make the case for avoidance.
High leverage leaves the business exposed if rates stay elevated or demand softens. A moderate moat offers some protection, but not enough to offset the ethical red flag at current valuation. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
NDSN trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-01Accumulation$322.67+0.1%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (7 analysts) rates it buy, with a mean price target of $314.
2026-10-25Accumulation$322.31+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (7 analysts) rates it buy, with a mean price target of $314.
2026-10-18Accumulation$322.31-2.7%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (7 analysts) rates it buy, with a mean price target of $314.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (7 analysts) rates it buy, with a mean price target of $314.
2026-09-18Markup · changed$313.94+1.6%Entry 8
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (7 analysts) rates it buy, with a mean price target of $314.
2026-08-19Accumulation$308.98+0.0%Entry 7
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (7 analysts) rates it buy, with a mean price target of $314. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-18Accumulation$308.98+0.0%Entry 6
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (7 analysts) rates it buy, with a mean price target of $314. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (7 analysts) rates it buy, with a mean price target of $314. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-06Markup$302.65+7.0%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (7 analysts) rates it buy, with a mean price target of $314.
2026-07-18Markup$282.73+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (7 analysts) rates it buy, with a mean price target of $314.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.